Akari Therapeutics, Plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Akari Therapeutics, Plc (AKTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $10.33 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-08-13
- Akari Therapeutics, Plc share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Akari Therapeutics, Plc share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2025-03-31 was $46.48.
- Akari Therapeutics, Plc share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2025 was $1.11, a 27.45% decline from fiscal 2024.
- Akari Therapeutics, Plc share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $1.53.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $10.33 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-19 | ||||
| 2025-12-31 | $1.11 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $1.45 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $59.60 10-Q · filed 2026-08-13 | $1.49 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $46.48 10-Q · filed 2026-05-19 | ||||
| 2024-12-31 | $1.53 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $2.96 10-Q · filed 2025-11-13 | ||||
| 2024-06-30 | $2.79 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |